{"id":1152,"date":"2016-11-08T18:20:37","date_gmt":"2016-11-08T18:20:37","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/?p=1152"},"modified":"2017-08-21T10:43:58","modified_gmt":"2017-08-21T10:43:58","slug":"primary-care-corner-with-geoffrey-modest-md-hiv-drug-costs-and-effectiveness-are-we-going-in-the-wrong-direction","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2016\/11\/08\/primary-care-corner-with-geoffrey-modest-md-hiv-drug-costs-and-effectiveness-are-we-going-in-the-wrong-direction\/","title":{"rendered":"Primary Care Corner with Geoffrey Modest MD: HIV Drug Costs and Effectiveness. Are We Going in the Wrong Direction?"},"content":{"rendered":"<p><strong>By Dr. Geoffrey Modest<\/strong><\/p>\n<p>An observational cohort study looked at patients on antiretroviral therapy (ART) for HIV,\u00a0finding that some of the most effective yet cheapest regimens are not being recommended for use today (see\u00a0Eaton EF. AIDS 2016; 30: 2215). I\u00a0have included the 340b pharmacy pricing, which is the reduced federal pricing available since 1992 to eligible health care organizations (mostly\u00a0Federally-funded clinics and public hospitals)\u00a0vs the AWP, average wholesale price, used in private pharmacies.<\/p>\n<p>Details:<\/p>\n<ul>\n<li>491 patients (mean age 36, 83% men, 61% African-American) initiating anti-retroviral therapy (ART) between 2007-2013, at the University of Alabama at Birmingham<\/li>\n<li>Durability (time from regimen initiation to discontinuation), used as a surrogate for the combo of\u00a0effectiveness and tolerability.<\/li>\n<li>Results for the 5 most common ART regimens used\u00a0during that time:\n<ul>\n<li>TDF\/FTC (tenofovir disoproxil fumarate\/emtricitabine)\u00a0with efavirenz (atripla): durability 40.1 months; 340b price $726.26<\/li>\n<li>TDF\/FTC with raltegravir: durability 47.8 months (longest); 340b price $1080.60<\/li>\n<li>TDF\/FTC with darunavir\/ritonavir: durability\u00a047.8 months (longest); 340b price $1153.00<\/li>\n<li>TDF\/FTC with atazanavir\/ritonavir: durability 31.9 months (shortest); 340b price $1070.88<\/li>\n<li>TDF\/FTC with rilpivirine: durability\u00a03 months; 340b price $917.50<\/li>\n<\/ul>\n<\/li>\n<li>Overall, combining durability\u00a0with\u00a0price, the efavirenz (atripla) regimen dominated,\u00a0with\u00a0the rilpivirine one\u00a0following closely behind<\/li>\n<\/ul>\n<p>Commentary:<\/p>\n<ul>\n<li>Several of the older treatments have been downgraded in recent guidelines, including atripla (TDF\/FTC\/EFV) for neuropsych effects of dizziness, anxiety, lack of concentration, vivid dreams and\u00a0suicidality (though large observational studies have not found increased suicidality) and complera (TDF\/FTC\/rilpivirine) since it is less effective in those with high HIV viral loads.<\/li>\n<li>The new guidelines do attach a comment that we should consider cost in determining the regimen, but they formally\u00a0downgraded the cheapest regimens. For a review of the guidelines, see\u00a0<a href=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2016\/07\/29\/primary-care-corner-with-geoffrey-modest-md-2016-hiv-treatment-guidelines\/\">https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2016\/07\/29\/primary-care-corner-with-geoffrey-modest-md-2016-hiv-treatment-guidelines\/<\/a> for the Intl Antiviral Society&#8211;USA guidelines,\u00a0or go to\u00a0<a href=\"https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf\">https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf<\/a> for the DHHS updated guidelines (these 2 do differ slightly, with the first one suggesting the TAF (tenofovir alafenamide)\u00a0regimens only, but the first-line regimens\u00a0are basically the most expensive of the list below)<\/li>\n<li>I did get today&#8217;s 340b\u00a0pharmacy costs for common HIV meds, for a 30-day supply (note: the 340b\u00a0cost is much lower and does not track well with the AWP)\n<ul>\n<li>Atripla (TDF\/FTC\/EFV): $688.93 (generic is still not available, but should be soon, which should drive down this cost)<\/li>\n<li>Truvada (TDF\/FTC): $428.61\u00a0(generic is still not available, but should be soon, which should drive down this cost)<\/li>\n<li>Raltegravir: $591.58<\/li>\n<li>Descovy (TAF\/FTC): $428.61 (ie, same price\u00a0as brand-name truvada, and probably because the drug company wants us to continue with this product instead of the switching to the generic truvada when available. And though TAF does not have the long clinical\u00a0trials of TDF, it does offer some real potential advantages in terms of decreasing the\u00a0renal and bone toxicities of TDF)<\/li>\n<li>Tivicay (dolutegravir): $832.44<\/li>\n<li>Odefsey (TAF\/FTC\/rilpivirine): $1716.13<\/li>\n<li>Genvoya (elvitegravir\/cobicistat\/TAF\/FTC): $1893.68<\/li>\n<li>Stribild (elvitegravir\/cobicistat\/TDF\/FTC): $1638.87 (though here, substituting TAF for TDF does seem to increase the cost&#8230;.)<\/li>\n<li>Prezcobix (darunivir\/cobicistat): $759.39<\/li>\n<li>Evotaz (atazanavir\/cobicistat): $700.70<\/li>\n<li>Triumeq (dolutegravir\/abacavir\/3TC): $1580.35<\/li>\n<\/ul>\n<\/li>\n<li>Just to put all of this in perspective:\n<ul>\n<li>The new drugs are really great, with excellent\u00a0acceptability (I\u00a0have had to stop dolutegravir only once for GI effects), along with remarkable efficacy, combined with much more &#8220;leniency&#8221; than the older drugs such as efavirenz\u00a0(one can miss more doses but maintain\u00a0continued viral suppression,\u00a0without developing resistance so easily)<\/li>\n<li>But the old drugs (especially atripla) were the ones which were\u00a0able to turn the AIDS from almost uniformly fatal to almost uniformly a chronic disease<\/li>\n<li>And, the vast majority of patients tolerated these drugs well.\u00a0The +\/- 90%\u00a0\u00a0who were able to continue on them had the same remarkable great\u00a0outcomes as with the new drugs (I\u00a0have rarely had to\u00a0change\u00a0my old patients on atripla to one of the newer formulations)<\/li>\n<li>And,\u00a0these old regimens are likely to get much cheaper when generics become available<\/li>\n<\/ul>\n<\/li>\n<li>So, what does this all mean? We live in an extremely expensive health care system (1\/3 of Massachusetts spending is for healthcare\/Medicaid), yet we have the remarkably opaque system where clinicians providing the care are &#8220;shielded&#8221; from its cost. Hospitals do not provide us with the cost of MRIs or colonoscopies, or the fact that at one hospital it is 2-3x the price of another. It\u00a0is not easy to find the actual costs of medications, and this cost can vary considerably from one pharmacy to another (again, it is a lot of work for us to find out the actual costs). Drug companies and hospitals, in these cases, have no interest in advertising costs &#8212; drug companies\u00a0promote the &#8220;newest and best&#8221; to us through sponsoring the studies and\u00a0advertising\u00a0aggressively (and expensively) to us and directly to consumers, highlighting their new cancer drug which increases life expectancy a couple of months at $100,000 per injection, etc etc. Ironically, we clinicians\u00a0as consumers would (mostly, I\u00a0assume) never tolerate buying other consumer\u00a0products without knowing their price and their relative value compared to other items of the same class. so, though I\u00a0have been prescribing these new HIV drugs to my newly diagnosed patients, I\u00a0think this article really does give pause and highlights the strange situation we are in in our increasingly expensive, increasingly unaffordable, intentionally cost-opaque\u00a0health care system, which in many ways does not lead to major improvements in community health or health care outcomes, yet with us as clinicians\u00a0inadvertently\u00a0being put in the position of how $$ is spent: a perfectly devised system to maximize the profits of the drug companies, hospitals, etc. And many of the people sitting on the committees\u00a0writing the new guidelines in medicine are financially supported by drug companies, etc, both for their research and personal financial gain, which really\u00a0should be seen as\u00a0an unacceptable conflict-of-interest.<\/li>\n<\/ul>\n<p>See\u00a0<a href=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2016\/04\/26\/primary-care-corner-with-geoffrey-modest-md-life-expectancy-and-income\/\">https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2016\/04\/26\/primary-care-corner-with-geoffrey-modest-md-life-expectancy-and-income\/<\/a> , a recent blog which includes reference to the\u00a0book <u>The Health Care Paradox<\/u>, which argues well that we in the US spend huge amounts of money per capita\u00a0on medical care but reap\u00a0really poor-to-mediocre improvements in health outcomes (e.g.,\u00a0infant mortality or life expectancy being lower than almost any other industrialized country), because we devote the vast majority of the medical care\u00a0$$ specifically\u00a0to health care and such a low percentage\u00a0to public health\/social programs that promote the prerequisites for good health: good employment, housing, food, supportive social environments, exercise programs,\u00a0day care\/elder care&#8230;&#8230;)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Primary Care Corner with Geoffrey Modest MD: HIV Drug Costs and Effectiveness. Are We Going in the Wrong Direction?  [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2016\/11\/08\/primary-care-corner-with-geoffrey-modest-md-hiv-drug-costs-and-effectiveness-are-we-going-in-the-wrong-direction\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":148,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14283],"tags":[],"class_list":["post-1152","post","type-post","status-publish","format-standard","hentry","category-archive"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/1152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/users\/148"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/comments?post=1152"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/1152\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media?parent=1152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/categories?post=1152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/tags?post=1152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}